MENU

Company news

The first patient in the Phase Ib trial of IMM01 successfully enrolled

Date:2021-10-26 Views:275

October 27, 2021, Shanghai, China.

     ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that IMM01, the drug candidate of  a SIRPα-Fc fusion protein targeting human CD47, successfully moves into Phase Ib trial, the first dose was given to a formally enrolled patient at the Second Affiliated Hospital of Nanchang University. The IMM01 phase Ib trial is being launched in more than 30 hospitals across the country, further establishing ImmuneOnco’s leading position in the area of research and development in CD47- targeting drugs.


    The first dose of IMM01 was administrated in the first patient with diffuse large B-cell lymphoma on October 26, 2021. IMM01 is a recombinant human SIRPα-antibody fusion protein. By blocking the binding of CD47 on tumor cells to SIRPα on macrophages, the inhibitory effect to tumor cells can be reversed. At the same time, the fusion protein can induce antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) through the Fc receptors on T cells and macrophages, and ultimately kills tumor cells.


    Dr. Tian Wenzhi, the founder and chairman of ImmuneOnco, said: "I am very pleased to learn that the first patient of Phase Ib of our IMM01-I project was successfully enrolled in the group. The advantage of IMM01 to other drugs targeting CD47 is that it completely avoids binding red blood cells, so that it will not cause serious anemia. At the same time, due to glycosylation modification, the immunogenicity of the drug is greatly reduced, and the PK of the drug is well improved, so that the bioavailability of the drug is significantly promoted. The results of the phase Ia clinical trial have initially confirmed the safety and tolerability of IMM01."


    "We will work closely with clinical experts and patients to accelerate the progress of clinical trial of IMM01, and make market launch of IMM01 at a faster pace, so that patients with relapsed and refractory cancers can benefit earlier.


About IMM01

    MM01 for injection is a new generation of immune checkpoint inhibitor with independent intellectual property rights, which is developed based on the "MAB-TRAP" technical  platform of  ImmuneOnco. Aiming at the immune regulatory CD47, it can activate the phagocytosis of macrophages on tumor cells and present tumor antigens to T cells. Thus, it takes powerful effects of tumor immunology. The IMM01 project faces the challenge of CD47 target drug research and development, and has been granted invention patents in China, Japan and the United States.



About ImmuneOnco

    Founded in June 2015 in the Zhangjiang Hi-Tech Park of the China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on the development and research of anti-tumor immunotherapy products, including bi-specific antibodies, novel recombinant proteins, and TankTM cellular therapy. The common feature of these products is to activate the patient's own immune system to exert the anti-tumor effects, and ultimately inhibit the endless growth of tumor cells and reverse the malignant symptoms, so that the patients gradually return to healthy. So far, several new anti-tumor drugs are in clinical research stage. ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017.